AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,202 INR | +3.21% |
|
+2.11% | +10.92% |
| 05-08 | India's Hindalco mulls seeking $1.2 bln in Novelis IPO, Bloomberg News reports | RE |
| 05-02 | Aurobindo Pharma Completes Sale of US Arm's Business Assets | MT |
| Sales 2024 * | 287B 3.44B 271B | Sales 2025 * | 315B 3.78B 298B | Capitalization | 683B 8.2B 646B |
|---|---|---|---|---|---|
| Net income 2024 * | 31.34B 376M 29.64B | Net income 2025 * | 37.92B 455M 35.86B | EV / Sales 2024 * | 2.32 x |
| Net cash position 2024 * | 18.34B 220M 17.34B | Net cash position 2025 * | 35.81B 430M 33.86B | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
17.9
x | Employees | 23,451 |
| Yield 2024 * |
0.35% | Yield 2025 * |
0.43% | Free-Float | 47.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aurobindo Pharma
More recommendations
More press releases
More news
| 1 day | +3.21% | ||
| 1 week | +2.11% | ||
| Current month | +4.24% | ||
| 1 month | +7.89% | ||
| 3 months | +15.52% | ||
| 6 months | +20.47% | ||
| Current year | +10.92% |
1 week
1 117.00
1 212.00
1 month
1 074.251 212.00
Current year
958.501 212.00
1 year
581.251 212.00
3 years
397.201 212.00
5 years
288.851 212.00
10 years
288.851 212.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 25/12/86 | |
| Director of Finance/CFO | - | 31/12/12 | |
B. Adi Reddy
CMP | Compliance Officer | - | 31/05/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 25/12/86 | |
| Founder | 66 | 25/12/86 | |
| Director/Board Member | 64 | 26/05/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.32% | 6 M€ | +6.07% | - | |
| 0.22% | 19 M€ | +9.88% | ||
| 0.12% | 11 M€ | +8.03% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 1,165 | +0.44% | 1,301,547 |
| 16/05/24 | 1,160 | +0.13% | 699,002 |
| 15/05/24 | 1,158 | -0.87% | 1,001,585 |
| 14/05/24 | 1,169 | -0.76% | 1,704,299 |
| 13/05/24 | 1,178 | +4.44% | 3,504,915 |
Delayed Quote NSE India S.E., May 18, 2024 at 08:19 am
More quotes
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
24/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
1,165
INR
Average target price
1,197
INR
Spread / Average Target
+2.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.92% | 8.19B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- AUROPHARMA Stock
